Sign in
CompletedNo phase

miRNA in Septic Acute Kidney Injury

Key facts

Who runs it
University Hospital Ostrava
Where
Czechia2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
211 people enrolled
Started
2 May 2024
Ended
31 Mar 2026
Type of study
Observational, 3 groups
Treatments tested
  • Laboratory examination to determine the presence of sepsis
  • Laboratory examination to determine the presence of sepsis and acute kidney injury
  • Laboratory examination to determine miRNA and biochemical parameters
Record updated
3 June 2026

Who can take part

Age
18 years to 100 years
Sex
Women and men

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • The study group of patients with sepsis with or without acute kidney injury
  • age > 18 years
  • newly diagnosed sepsis or septic shock with or without acute kidney injury; Healthy volunteers
  • no evidence of infection on clinical or laboratory examination
  • age > 18 years
  • signed informed consent

Who cannot take part

  • patients on chronic dialysis treatment, or after renal transplantation; Healthy volunteers
  • chronic kidney disease at stage 4 or 5 according to KDIGO recommendations (KDIGO) for chronic kidney disease 2024
  • acute or chronic infection
  • renal disease
  • age < 18 years
  • The study group of patients with sepsis with or without acute kidney injury

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Acute kidney injury is a common and serious complication of sepsis and septic shock, which may be associated with a worse outcome of the patient's condition. The exact pathophysiological mechanism of septic acute kidney injury remains a challenge. One of the possible causes appears to be endothelial dysfunction and mitochondrial damage of renal tubular cells. The aim of this study is to identify specific microRNAs associated with these pathophysiological events in sepsis and septic acute kidney injury. And to establish a new potential diagnostic or therapeutic target for the prevention or treatment of septic acute kidney injury.

The 3 groups in the trial

  • Critically ill adult septic patients without acute kidney injury

    The patients in this group will be screened clinically and by standard laboratory biochemical methods to determine sepsis diagnosis according to SEPSIS 3 (1). Blood samples for obtaining serum/plasma of the patients will be taken on the 1st and 4th day of sepsis diagnosis.

    Treatment: Laboratory examination to determine the presence of sepsis

  • Critically ill adult septic patients with acute kidney injury

    The patients will be screened clinically and by standard laboratory biochemical methods to determine sepsis diagnosis according to SEPSIS 3 and acute kidney injury according to KDIGO 2012 (2). Blood samples for obtaining serum/plasma of the patients will be taken on the 1st and 4th day of sepsis diagnosis.

    Treatment: Laboratory examination to determine the presence of sepsis and acute kidney injury

  • Healthy volunteers

    The blood samples for miRNA and biochemical parameters will be collected once, after randomization.

    Treatment: Laboratory examination to determine miRNA and biochemical parameters

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Specific miRNA Associated With Endothelial Dysfunction and Mitochondrial Damage in Patients With Septic Acute Kidney Injury
Publications
Record updated
3 June 2026